Molecular Genetic Mechanisms of Infantile Epilepsies and the Impact of Genetic Diagnosis
Recruiting · NCT06701084 · Interventional (participants receive a specific treatment) · Lead sponsor: Boston Children's Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Genomic Sequencing
What this trial is about
The goal of this study is to discover new genetic causes of infantile epilepsies and evaluate the impact of these discoveries on infants with epilepsy and their families.
Who can take part
Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Seizure onset at less than 12 months of age
- Enrollment within 6 weeks of seizure-related presentation
- Patient at Boston Children's Hospital
Exclusion criteria
- Simple febrile seizures
- Acute provoked seizures (e.g., due to sepsis, hemorrhage, electrolyte abnormality, cerebral infarction, hypoxic ischemic encephalopathy, non-accidental injury)
- Genetic or acquired cause of epilepsy already identified, including brain magnetic resonance imaging findings consistent with a specific genetic etiology (e.g., tuberous sclerosis complex)
- Deceased prior to enrollment
- Parent Criteria Inclusion Criteria - Parent of eligible infant (see above)
- Exclusion Criteria
- \- Not the legal guardian of the eligible infant
Where it is running
1 location listed across 1 US state.
- Boston Children's Hospital - Boston, Massachusetts, United States